1. BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3‐YEAR FOLLOW‐UP FROM THE RIALTO TRIAL. (12th June 2019) Authors: Pettitt, A.; Kalakonda, N.; Cicconi, S.; Murphy, C.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; Rassam, S.; Duncombe, A.S.; Cervi, P.; Paneesha, S.; Aldouri, M.; Fox, C.; Knechtli, C.; Hamblin, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 217 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL. (June 2017) Authors: Pettitt, A.R.; Kalakonda, N.; Polydoros, F.; Bickerstaff, M.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; Rassam, S.; Duncombe, A.S.; Jenner, M.; Cervi, P.; Paneesha, S.; Aldouri, M.; Fox, C.P.; Knechtli, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗